GoodRx Holdings, Inc. (GDRX) Analisi del titolo

Panoramica dell'azienda

GoodRx Holdings, Inc. operates within the healthcare sector, specifically focusing on the health information services industry, where it provides digital tools enabling consumers to compare prescription drug prices and reduce costs in the United States. This positioning allows the company to function as a price comparison platform that delivers geographically relevant and curated data to end-users seeking affordability in pharmaceuticals. The organization employs a workforce of 697 individuals and holds a market capitalization of $739.96 million, reflecting its standing as a mid-cap entity within the specialized health technology landscape. With annual revenue reaching $796.85 million, these financial figures indicate that the company has established a significant operational footprint, generating substantial top-line volume while maintaining a valuation that suggests investor interest in its digital infrastructure and user base expansion capabilities.

Salute finanziaria

The company reported total revenue of $796.85 million over the trailing twelve months, with net income standing at $30.44 million and EBITDA totaling $122.31 million. The substantial disparity between the $796.85 million revenue and the $30.44 million net income highlights a cost structure where operating expenses, including cost of sales, administrative costs, and taxes, absorb the majority of gross earnings before reaching the bottom line. Free cash flow stands at $81.94 million, which demonstrates a strong capacity to generate liquidity independent of financing activities and supports financial flexibility for strategic initiatives or debt servicing. The gross margin is reported at 92.8%, indicating a highly scalable business model with low direct costs relative to revenue, while the operating margin of 19.0% suggests effective control over overhead expenditures. However, the profit margin of 3.8% reveals that significant non-operating expenses or tax burdens impact the final earnings, compressing the return on top-line sales. On the balance sheet, the company holds $261.82 million in cash against total debt of $542.81 million, resulting in a debt-to-equity ratio of 88.08% that characterizes a leveraged financial structure where liabilities exceed equity. Despite the leverage, the current ratio of 2.61 indicates robust short-term liquidity, ensuring the firm can comfortably meet its immediate obligations with current assets. Return on equity is 4.5% and return on assets is 4.8%, metrics that collectively suggest a moderate level of management effectiveness in generating returns relative to the capital invested by shareholders and utilized in operations.

Valutazione del valore

The trailing twelve-month P/E ratio is 24.00, whereas the forward P/E is significantly lower at 5.88, implying that the market expects a substantial turnaround in earnings performance or that current earnings are being suppressed by temporary factors not reflected in future projections. The price-to-book ratio stands at 1.20, indicating that the stock trades at a slight premium over its book value, suggesting investors value the company's intangible assets and growth potential above its tangible net worth. Alternative valuation metrics such as the price-to-sales ratio of 0.93 and the EV/EBITDA of 8.35 provide context that the company is valued conservatively relative to its sales and earnings power, particularly when considering the low forward multiple. The stock has traded between a 52-week low of $1.77 and a 52-week high of $5.81, with the current share price sitting at a level that reflects recent market volatility and sentiment shifts within the healthcare technology sector. The beta of 1.47 signifies that the stock exhibits higher price volatility than the broader market, moving more aggressively in response to general market swings, which aligns with the characteristics of a small-cap biotech or healthcare services play.

Growth & Income

Revenue growth year-over-year decreased by 1.9%, while earnings growth year-over-year declined by 9.7%, indicating that earnings are contracting at a faster rate than revenue, which points to margin pressure or one-time costs impacting the bottom line more severely than the top line. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all of its net income to reinvest into business growth rather than distributing cash to shareholders. This retention strategy aligns with the company's stage of development, prioritizing capital expenditure and operational scaling over income generation for current investors. Overall, the growth and income profile is characterized by a contraction in profitability metrics despite a relatively stable revenue base, with no income support from dividends and a high sensitivity to market fluctuations given the elevated beta.